Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02214953
Recruitment Status : Completed
First Posted : August 13, 2014
Last Update Posted : August 13, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To compare the oral bioavailability and rate of absorption of four prototype extended-release (ER) formulations with BI 11634 (single doses) to immediate-release (IR) tablets in healthy male volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: BI 11634 ER formulation A Drug: BI 11634 ER formulation B Drug: BI 11634 ER formulation M Drug: BI 11634 ER formulation C Drug: BI 11634 IR tablet Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Randomised, Single-dose, Four-way Cross-over Formulation Finding Study of the Oral Bioavailability of Four Prototype Extended Release Formulations With 25 mg BI 11634, and Intra-individual Comparison to Immediate-release Tablets (25 mg) in Healthy Male Volunteers
Study Start Date : October 2007
Actual Primary Completion Date : December 2007

Arm Intervention/treatment
Experimental: BI 11634 ER formulation A Drug: BI 11634 ER formulation A
Experimental: BI 11634 ER formulation B Drug: BI 11634 ER formulation B
Experimental: BI 11634 ER formulation M Drug: BI 11634 ER formulation M
Experimental: BI 11634 ER formulation C Drug: BI 11634 ER formulation C
Active Comparator: BI 11634 IR tablet Drug: BI 11634 IR tablet



Primary Outcome Measures :
  1. AUC0-∞ (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: up to 48 hours after drug administraton ]
  2. Cmax (maximum measured concentration of analyte in plasma) [ Time Frame: up to 48 hours after drug administraton ]

Secondary Outcome Measures :
  1. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) [ Time Frame: up to 48 hours after drug administration ]
  2. tmax (time from dosing to the maximum concentration of the analyte in plasma) [ Time Frame: up to 48 hours after drug administration ]
  3. λz (terminal rate constant in plasma) [ Time Frame: up to 48 hours after drug administration ]
  4. t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: up to 48 hours after drug administration ]
  5. MRTpo (mean residence time of the analyte in the body after oral administration) [ Time Frame: up to 48 hours after drug administration ]
  6. CL/F (apparent clearance of the analyte in the plasma after extravascular administration) [ Time Frame: up to 48 hours after drug administration ]
  7. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) [ Time Frame: up to 48 hours after drug administration ]
  8. Fluctuation parameter Cmax/C24 ratio [ Time Frame: up to 48 hours after drug administration ]
  9. Maximum prolongation of blood coagulation time [ Time Frame: up to 48 hours after drug administration ]
    by HepTest® (Haemachem Inc.)

  10. Number of subjects with adverse events [ Time Frame: up to 8 days after last drug administration ]
  11. Number of subjects with clinically significant findings in vital signs (blood pressure, pulse rate) [ Time Frame: up to 8 days after last drug administration ]
  12. Number of subjects with clinically significant findings in ECG [ Time Frame: up to 8 days after last drug administration ]
  13. Number of subjects with clinically significant findings in laboratory tests [ Time Frame: up to 8 days after last drug administration ]
  14. Assessment of tolerability by investigator on a 4-point scale [ Time Frame: up to 8 days after last drug administration ]
  15. % Inhibition of Factor Xa [ Time Frame: up to 48 hours after drug administration ]
    by Russel's Viper Venom test (RVV)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Caucasian males according to the following criteria, based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead ECG, clinical laboratory tests
  • Age ≥21 and ≤45 years
  • Haemoglobin within the normal ranges.
  • Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
  • Signed and dated written informed consent prior to admission to the study in accordance with good clinical practice (GCP) and the local legislation

Exclusion Criteria:

  • Relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Relevant surgery of gastrointestinal tract
  • History of any bleeding disorder or acute blood coagulation defect, for the subject itself or any person of his family as far as known
  • History of gastric ulcera and cholecystectomy
  • Occult blood in faeces
  • Relevant diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Relevant chronic or acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Use of acetylsalicylic acid or any other non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks of study start until the end of study
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Alcohol abuse (more than 40 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to understand and comply with protocol requirements, instructions and protocol stated restrictions, the nature, scope and possible consequences of the study
  • Subjects with a history within the past six weeks of closed-head or torso trauma or deceleration injury such as an automobile accident or fall from a significant height

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02214953    
Other Study ID Numbers: 1234.7
First Posted: August 13, 2014    Key Record Dates
Last Update Posted: August 13, 2014
Last Verified: August 2014